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Is Routine Testing Mandatory
or Voluntary?
The AIDS Treatment Activists Coalition
(ATAC) is a national coalition of AIDS
activists, many of whom are living with
HIV/AIDS, working together to end the
AIDS epidemic by advancing research on
HIV/AIDS. ATAC’s Access to Health Care
for the Incarcerated working group has the
goal of increasing access to health care
for incarcerated people through strategy
coordination, information sharing, train-
ing, and advocacy for allied individuals,
groups, and communities. The Access to
Health Care for the Incarcerated working
group opposes the call for routine HIV test-
ing recommended in the recent editorial
commentary entitled “HIV Infection Be-
hind Bars” by Boutwell and Rich [1].
We believe that routine HIV testing in
prison is virtually synonymous with man-
datory testing. Prisoners often receive no
pretest counseling or education about HIV
infection; frequently, they are unaware of
the implications of testing positive for HIV
while incarcerated. Consent often means
something completely different in prison
than it does outside of prison. Many pris-
oners are unaware that they have con-
sented to HIV testing—or that they ac-
tually were tested for HIV, despite the
consent form.
We agree wholeheartedly that identifi-
cation of infected individuals is an im-
portant step in addressing HIV infection
in any setting. However, prisoners do not
have guaranteed access to the standard of
care for HIV treatment, so beginning the
process of addressing HIV disease behind
bars must entail providing access to coun-
seling, education, and the standard of care
for HIV treatment, as defined by the De-
partment of Health and Human Services’
guidelines [2]. Without guaranteed access
to quality care, any testing will only result
in continued retaliation, stigmatization,
threats, lack of confidentiality, and sub-
standard medical care.
The disproportionately high number of
HIV-infected persons in our prisons is
more than “a challenge to correctional
health systems” and a “public health op-
portunity” [1]. It is a human rights ca-
tastrophe of vast proportions, and it chal-
lenges our society as a whole. Our
priorities must be ordered by the thou-
sands of prisoners whose lives are on the
line.
The commentary by Boutwell and Rich
[1] echoes the unfortunate new position
on mandatory testing for prisoners cur-
rently held by the Centers for Disease
Control and Prevention (CDC). Although
testing may have led to better treatment
in Rhode Island (which, not surprisingly,
has the smallest correctional system in the
country), this is not the case in most state
prison systems. The experience inside
most prison systems is that testing does
not lead to education, care, and treatment.
It leads to discrimination, segregation, and
just plain poor care. HIV-infected pris-
oners are not eligible for many prison jobs
and programs, such as work-release pro-
grams and halfway house placement. De-
spite the success of peer education in the
community, behind the walls, there are
fewer HIV peer education programs than
ever before. The reality is that testing pos-
itive inside feels like—and, in some cases,
is—a death sentence.
We must ask whether it is in anyone’s
interest for people inside the walls of
prison to be treated any differently than
people on the outside.
Mandatory HIV testing is a vast depar-
ture from commonly held public health
standards. Is this a precursor to a broader
CDC policy that all people should be
tested, regardless of consent? Right now,
people outside of prison walls have the
right to make informed decisions about
whether to be tested for HIV. Prisoners
deserve the same rights.
Our first priority must be programming
that provides education, counseling, and
a continuum of quality care and treatment
to inmates while they are imprisoned and
after they have been released.
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Reply to Walker et al.
Sir—We laud Mealy et al. [1] for bring-
ing more attention to the complex issue
of HIV testing for incarcerated popula-
tions in the United States. We share their
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stated goals of advancing research to end
the AIDS epidemic and increasing access
to health care for incarcerated people,
including provision of education, coun-
seling, medical care, and linkage to care
in the community upon discharge for
HIV-infected inmates. Our original article
described the high burden of disease in
the incarcerated population and recom-
mended ways to address this from a med-
ical and public health perspective [2]. It is
true that we did not emphasize the human
rights tragedy that exists in our society, in
which minority and impoverished popu-
lations are disproportionately incarcer-
ated, and the underlying causes of racism,
addiction, mental illness, and poverty are
not addressed. This is a problem that we
all must strive to solve.
A few key misconceptions in the letter
from Mealy et al. [1] warrant specific clar-
ification. The most significant misconcep-
tion is their incorrect equation of routine
testing with mandatory testing. Testing
can be voluntary (“opt in”), mandatory
(no choice—all must get tested), or rou-
tine (“opt out”). Each option has its pros
and cons. Voluntary testing preserves
maximal autonomy but fails to identify
many infected individuals and fails to offer
testing to noninfected individuals, a pro-
cedure that, in itself, can cause individuals
to reflect upon their risk behaviors and
reduce them (primary prevention). Vol-
untary testing also may increase stigma-
tization, because only those who admit to
having risk factors get tested. Mandatory
testing can identify nearly all infected in-
dividuals in the most timely fashion, but
it does not provide the individuals with
any choice. This is analogous to what hap-
pens in most correctional facilities with
regard to screening for tuberculosis, an-
other potentially fatal, treatable contagious
disease. We do not advocate mandatory
HIV testing, because we believe that the
same benefits (identification and treat-
ment of most infected individuals, as well
as some prevention) can be achieved with
a well-designed system of routine testing.
Routine testing preserves the ability of the
individual to opt out. There are several
examples of programs that have been able
to achieve testing rates of close to 90%
[3], and we have found this to be well
accepted by inmates. Routine HIV testing
of prisoners was able to identify one-third
of all known HIV-infected individuals in
the entire state of Rhode Island [4].
Testing for HIV is the first step in link-
age to care, whether in the community or
in the correctional setting. Linkage to care
includes connecting individuals with post-
test counseling and education to identify
opportunities to decrease personal risk of
HIV acquisition or transmission and to
understand the importance of accessing
medical care to prolong survival.
Incarcerated individuals are among the
most stigmatized and disenfranchised. As
such, they are often systematically ex-
cluded from accessing health services in
the community. Because it is imperative
to ensure linkage to care after a diagnosis
of HIV infection for individuals in the
community, so too is it for individuals in
the correctional setting. The challenges of
doing this in the two settings are unique;
however, they are not insurmountable, as
evidenced by model programs [5, 6]. In
fact, the constitutional standard estab-
lished by the US Supreme Court in Estelle
v. Gamble in 1976 offers a unique oppor-
tunity and requirement to provide appro-
priate health care to incarcerated individ-
uals, a protection that does not exist in
the community setting. Thus, the en-
counter with the correctional health sys-
tem is an incredible opportunity to pro-
vide health care to individuals from
traditionally underserved and hard-to-
reach communities. Some studies have
found that 3 of 4 HIV-infected inmates
began their first antiretroviral regimen
while incarcerated [7]. With the wide-
spread use of effective antiretroviral ther-
apy in the late 1990s, mortality rates for
HIV infection plunged in the United
States. In the correctional setting, there
was a parallel 75% decrease in mortality
rates [8]. Correctional health care systems
are not perfect at providing care for HIV-
infected persons, but clearly, many HIV-
infected inmates are getting access to
treatment.
Mealy and colleagues’ [1] dismissal of
Rhode Island as the “smallest correctional
system in the country” is neither accurate
(7 states have smaller correctional popu-
lations) nor on point. Model programs,
such as that in Rhode Island, demonstrate
feasibility and effectiveness. Large depart-
ments of corrections often comprise nu-
merous smaller facilities; thus, implemen-
tation in other venues is more a matter of
process and content than scale.
To reject use of a diagnostic test because
the health care system is imperfect is to
tacitly accept the shortcomings of the bro-
ken system and thus to be complicit in
systematically excluding individuals sub-
ject to that system from accessing vital
health information. This is certainly not
the intention of any advocate for incar-
cerated individuals. We all must insist that
correctional health care services do a bet-
ter job of addressing what is known to be
a disproportionately high burden of in-
fectious diseases among the populations
they are charged to serve [9].
The time is now to address the need for
improved HIV testing and linkage to care
in the incarcerated population. As routine
testing becomes more and more encour-
aged in the community, this trend should
not lag behind in the correctional setting.
Indeed, this is an area where correctional
health systems should be on the forefront
of leadership in this epidemic. As HIV
testing in high prevalence areas becomes
routine in the community, there is no de-
fensible reason for this service to be denied
to those behind bars. The sooner that
HIV-infected prisoners are aware of their
diagnoses, the more likely they can begin
to receive life-saving treatment and, per-
haps, at the same time reduce transmission
to others. Our challenge is to ensure that
timely diagnosis and treatment are offered
to as many individuals as possible.
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Does Counseling Increase
Sustained Benefit of HAART
among Prison Inmates after
Release to the Community?
Sir—The lack of sustained effectiveness of
HAART after release to the community of
HIV-infected inmates treated in prison
was well demonstrated by Springer et al.
[1] in a recent article. This disappointing
result occurred even though all of the pa-
tients scheduled for release were referred
for transitional case management services
to a community-based organization and
were provided with a 2-week supply of
medications, a medical appointment with
an HIV care provider, emergency housing
and food, and assistance with other iden-
tified unmet needs.
In Italy, 7.5% of the ∼56,000 inmates
are HIV infected (Ministry of Justice,
Dipartimento dell’Amministrazione Pen-
itenziaria, personal communication); it is
estimated that approximately one-third
of them are receiving treatment with an-
tiretroviral drugs. Our data on the effec-
tiveness of HAART in the prison setting
are consistent with those of Springer
et al. [1]; however, in some of the 220
Italian prisons, the implementation of
directly observed treatment (DOT) has
been found to increase the proportion of
patients with undetectable HIV RNA
levels [2].
We also observed that interruption of
HAART after release from the prison is a
common event. As suggested by Springer
et al. [1] and as emphasized in the editorial
commentary by Boutwell and Rich [3],
there is a need for implementation of
more-effective programs to reduce the
probability of discontinuation of and/or
reduced compliance with therapy. These
programs must prevent use of illegal drugs
and alcohol, homelessness, and the relapse
of other behavior that may interfere
with adherence to antiretroviral drug
treatment.
To this end, in January 2001, we started
an intensive counseling program that ad-
dressed sustained correct use of HAART.
During their detention, prison inmates
met with the medical staff of drug treat-
ment units who were in charged with ob-
serving them after release.
The study was conducted in 4 prisons
on Sardinia island; the prisons were lo-
cated in the towns of Alghero, Macomer,
Tempio Pausania, and Sassari. Of ∼500
inmates, 16.4% were HIV infected. DOT
was implemented in only 1 of the 4 pris-
ons. During the 36-month study period,
a total of 153 HIV-infected patients who
were receiving HAART were released from
prison (59 patients in 2000, 51 in 2001,
and 43 in 2002). All of the subjects were
injection drug users, and all attended the
same drug treatment unit after prison
release.
We compared the proportion of pa-
tients sustaining HAART among those re-
leased in the 12 months before versus the
24 months after the initiation of the coun-
seling program (i.e., the year of 2000 ver-
sus the years of 2001–2002). The propor-
tion of patients with an HIV RNA level
of !50 copies/mL at the time of release
from the prison increased from 20
(33.9%) of 59 subjects in 2000 to 24
(47.1%) of 51 subjects in 2001 ( )P 1 .05
and to 27 (62.8%) of 43 subjects in 2002
(OR, 3.29; 95% CI, 1.34–8.15; ).P ! .01
Compared with the year 2000, when only
7 (12.5%) of 56 patients were found to
continue HAART, as measured by fre-
quency of follow-up visits and drug dis-
tribution by the community staff after the
release from the prison, the proportion
increased to 17 (37.8%) of 45 patients in
2001 (OR, 4.25; 95% CI, 1.43–13.01; P !
) and to 20 (52.6%) of 38 patients in.01
2002 (OR, 7.77; 95% CI, 2.56–24.66; P !
). Undectectable HIV RNA levels oc-.0001
curred in 5 (71.4%) of 7 patients in 2000,
increasing to 14 (82.3%) of 17 patients in
2001 and to 16 (80%) of 20 patients in
2002.
Our data suggest that an intensive
counseling program that addresses crea-
tion of a relationship between the inmate
and the medical team committed to pa-
tient clinical follow-up outside the prison
322 • CID 2004:40 (15 January) • CORRESPONDENCE
may improve adherence both in prison
and in the community after release, at least
in countries with a high proportion of in-
jection drug users among HIV-infected
inmates.
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Reply to Babudieri et al.
Sir—Development of novel interventions
for vulnerable populations of prisoners as
they are released to the community is ur-
gently needed. According to data we pre-
sented, case management services alone
appear to be inadequate [1]. Babudieri et
al. [2] describe a novel counseling pro-
gram that they believe has contributed not
only to virological success in subjects in
the correctional setting, but also to con-
tinued success in subjects after release
from prison. They should be commended
for recognizing the problem and address-
ing an obstacle that many view as insur-
mountable. Notwithstanding the limita-
tions of their small sample size and the
use of a preintervention/postintervention
analytic approach, there is merit in ex-
amining the lessons learned from their
experience.
The high rates of viral suppression ob-
served 2 years after implementation of the
intervention are impressive. Several ques-
tions regarding the effect of the interven-
tion, however, remain. Unlike the situa-
tion in the United States and elsewhere,
the Sardinian experience suggests that all
released prisoners are linked to continued
drug treatment programs after release. The
lack of a control group leads us to spec-
ulate that several additional factors may
have contributed to the described success.
Correctional and community HIV care
providers may have developed enhanced
counseling skills, may have increased their
diagnosis and treatment of comorbid
mental illness among the released pris-
oners, or may have prescribed simpler, less
toxic, and more potent regimens as cli-
nicians and health care systems began to
embrace the importance of adherence [3].
It is also possible that sentencing laws or
treatment practices changed over the ob-
servation period. For instance, a greater
number of prisoners released on proba-
tion or parole may result in increased rates
of abstinence from illicit drug use because
of the stringent and often punitive con-
ditions of release. A description of the
types of linkages, amount of education
provided, and the duration of success after
release to the community would further
inform us regarding the benefit of their
program.
Irrespective of the extenuating circum-
stances, novel approaches that sustain the
benefit of antiretroviral therapy between
the correctional and community settings
must be developed and tested using rig-
orous, unassailable, controlled trials. Only
such trials will result in policy changes. We
recently reported, in a randomized, con-
trolled trial of directly administered anti-
retroviral therapy, that supervised therapy
was superior at reducing viral load and
increasing CD4 lymphocyte count, com-
pared with self-administered therapy,
among HIV-infected drug users [4]. The
details of the intervention have been de-
scribed elsewhere [5]. These data suggest
that provision of structure and social sup-
port provide benefit to HIV-infected drug
users prescribed antiretroviral therapy—
perhaps this might be applicable for re-
leased prisoners. Drug treatment pro-
grams that provide effective structure and
support, such as prescription of metha-
done or buprenorphine, are absent from
most prisons and their respective release
programs and should be considered in fu-
ture interventions [6]. The Sardinian ex-
perience appears to integrate drug treat-
ment into the prison and postrelease
program—a wise and likely beneficial con-
tribution to success. Direct access to such
structured programs, recommended by
the World Health Organization [7], would
likely result in improved outcomes for
HIV-infected prisoners. Unfortunately, no
empirical studies have been conducted to
date. Interventions for released prisoners
must incorporate elements that address
social instability, untreated substance
abuse disorders, and psychiatric condi-
tions and that provide structure to oth-
erwise disorganized and chaotic lives. It is
incumbent on science and society to ren-
der beneficial and effective antiretroviral
therapy to everyone affected by HIV/
AIDS, including released prisoners.
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Sonographic Assessment
of Lipodystrophy in HIV-
Infected Patients: Some
Open Questions
Sir—We have read with interest the article
by Asensi et al. [1] because we are con-
ducting a similar study. The sonographic
assessment of lipodystrophy in human im-
munodeficiency virus (HIV)–infected pa-
tients who are treated with HAART has
been the subject of recent publications [1,
2]. Ultrasonography is a more practical
method than CT scanning and dual-
energy X-ray absorptiometry; its lack of
ionizing radiation, low cost, availability,
simplicity, and reproducibility, as well as
its acceptability among patients, make it
an ideal tool for diagnosis of lipodystrophy
and for early identification of subcuta-
neous fat thickness reduction and visceral
fat increase. We have encountered some
methodological issues that need to be ad-
dressed, if the potential of ultrasonogra-
phy is to be fully exploited.
A good correlation between the findings
of ultrasonography and CT scanning has
been demonstrated for the measurement
of visceral fat in patients who do not have
HIV infection [3]. However, no such data
are available for HIV-infected patients and
with regard to subcutaneous fat thickness.
Given the importance of a correlation be-
tween the findings of ultrasonography
and CT scanning, which remains the gold
standard, ultrasonography measurements
should be validated with CT scanning, at
least in a preliminary group.
Subcutaneous fat thickness is related
to the body mass index (BMI) in HIV-
infected patients [4], who tend to have an
increased amount of visceral fat when
their BMI is 127. Although Asensi et al.
[1] claim that there is no correlation be-
tween BMI, subcutaneous fat thickness,
and perirenal fat diameter, all of their pa-
tients had a BMI of !27. We believe that
the cutoff values of all measurements, par-
ticularly that of perirenal fat diameter,
should be readjusted for patients with a
BMI of 127, to avoid a possible bias.
Sex-related differences in body fat dis-
tribution are still a controversial issue [5,
6]. In our cohort, crural and brachial sub-
cutaneous fat thickness values were higher
in women than in men, in both HIV-
positive and HIV-negative patients, and
we feel that this finding warrants the di-
vision of the cohort into 2 subgroups.
There is no such distinction made in the
article by Asensi et al. [1]. In fact, the low
number of female patients in their cohort
could represent an additional source of
bias. The reproducibility of their results in
a female group is a crucial point, partic-
ularly with regard to the promising pre-
dictive role of perirenal fat diameter [1].
Dismetabolic abnormalities, such as
dislipidemia and insulin resistance, have
been described in hepatitis C virus–
infected patients [7, 8], and these abnor-
malities are strictly related to the increase
of visceral fat. This could be a source of
bias in the evaluation of visceral fat and
secondarily subcutaneous fat thickness in
patients coinfected with HIV and hepatitis
C virus with lipodystrophy. Because hep-
atitis C virus–infected patients are nu-
merous in the series of Asensi et al. [1],
this bias in the assessment of perirenal fat
diameter cannot be avoided if one fails
to include those patients in a specific
subgroup.
The ability of ultrasonography to re-
place—partially or completely—other
more cumbersome and expensive meth-
ods needs be clearly defined, given what
is at stake. The interruption of a life-saving
treatment such as HAART or a switch of
the regimen to nonnucleoside reverse-
transcriptase inhibitors because of im-
pending lipodystrophy, a serious and non-
reversible condition, are very important
steps to take and require the support of a
proven and fully standardized method.
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Reply to Gulizia et al.
Sir—We agree with Gulizia et al. [1] that
the value of ultrasonography to assess the
visceral fat and subcutaneous fat thickness
of HIV-infected patients has to be vali-
dated by comparison with other objective
methods, such as CT scanning. Using a
more subjective tool—the score of the
body fat changes directly observed by
HIV-infected patients and their physicians
during every follow-up visit by use of cri-
teria published elsewhere [2]—we have
found a significant correlation between the
score of the directly observed facial and
abdominal fat changes and the echo-
graphic malar (Bichat) subcutaneous fat
thickness ( ; ) and ab-rp 0.280 P ! .001
dominal subcutaneous fat thickness
( ; ). In addition, a sig-rp 0.180 P ! .001
nificant correlation between the score of
the directly observed abdominal fat
changes and the visceral fat measured as
the perirenal fat diameter (PRFD) was also
found ( ; ) (unpublishedrp 0.320 P ! .001
data). However, we observed no signifi-
cant correlation between the score of the
directly observed changes in arm or thigh
fat and the subcutaneous fat thickness of
the limbs, as assessed by ultrasonography.
As suggested by Gulizia et al., the body
mass index has to be considered, especially
for overweight patients. To avoid a pos-
sible bias in using the PRFD measure, we
recommend using a new adjusted PRFD,
which represents the ratio PRFD:body
mass index. By use of adjusted PRFD and
receiver operating characteristic curves,
the most discriminant pre-HAART base-
line adjusted PRFD for predicting the de-
velopment of lipodystrophy at the end of
the 27-month follow-up period was
0.118. Measurement of the adjusted
PRFD had identical sensitivity but was
slightly more specific than measurement
of the PRFD (sensitivity, 85.3%; specificity,
77.3%) [3]. The most discriminant ad-
justed PRFD for predicting the develop-
ment of lipodystrophy during receipt of
HAART was 0.182, although measure-
ment of the adjusted PRFD had a discri-
minant power that was identical to that
of measurement of the PRFD (sensitivity,
100%; specificity, 75.7%).
We also agree with Gulizia et al. [1] that
the small number of women (18 patients
[24.3%]) in our series—which was mostly
due to the predominance of males among
intravenous drug users in Spain [4], many
whom are coinfected with hepatitis C virus
(29 patients [39.2%])—could represent a
bias due to differences in sex, status of
hepatitis C virus coinfection, and body fat
distribution.
Our group and others have reported
that coinfection with hepatitis C virus in-
creases the level of lipodystrophy (mostly
lipoatrophy) in HIV-infected patients,
perhaps because of liver mitochondrial
toxicity, although mitochondrial toxicity
also decreases the serum levels of choles-
terol and triglycerides, probably because
of liver damage due to hepatitis C virus
infection [5–10]. Therefore, coinfection
with HIV and hepatitis C virus could have
consequences for subcutaneous fat thick-
ness and visceral fat changes, and this
should be considered as well.
Our study was conducted to evaluate
the usefulness of several parameters,
mainly echographic measurements to pre-
dict lipodystrophy in a nonselected pop-
ulation of HIV-infected individuals that
was considered as a whole. The sample size
of this pilot study was relatively small, se-
verely limiting the evaluation of different
subgroups that could be of interest. Fur-
ther multicenter studies that include
higher numbers of HIV-infected patients
who are at baseline and receiving HAART,
and that include specific subgroups of fe-
males and people coinfected with hepatitis
C virus and HIV, are needed to validate
the utility of ultrasonography in the as-
sessment of subcutaneous fat thickness
and visceral fat in HIV-infected patients,
as well as to confirm the value of PRFD
and adjusted PRFD measures as predictors
of lipodystrophy.
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Table 1. Amino acid sequence differences in diphtheria toxin of
Corynebacterium diphtheriae, Corynebacterium ulcerans X959, C. ul-











2 Ser Asn Asn Asn
14 Leu Ile Leu Leu
22 Ser Ser Leu Leu
31 Val Asp Val Val
67 Thr Ala Thr Ala
116 Val Ile Ile Ile
183 Ala Ala Glu Glu
210 Ala Ser Ser Ser
233 Val Ala Ala Ala
262 Thr Ile Thr Thr
277 Gln Gln Arg Gln
294 Thr Val Val Val
296 Pro Ser Ser Ser
305 Ala Ser Ser Ser
314 Ile Val Val Val
317 Glu Lys Lys Lys
378 Ile Leu Leu Leu
415 Leu Val Val Val
417 Asp Gly Gly Gly
421 Val Ala Ala Ala
432 Arg Lys Lys Lys
491 Gly Asp Asp Asp
492 Asp Ala Ala Ala
493 Val Thr Thr Thr
500 Ser Thr Thr Thr
518 Arg Arg Thr Arg
527 Asn Asp Asp Asp
529 Ile Thr Thr Thr
530 Ser Pro Pro Pro
531 Ser Leu Leu Leu
532 Asp Ser Ser Ser
535 Gly Asp Asp Asp
556 Phe Ala Ala Ala
558 Ile Val Val Val
NOTE. Bold face indicates a change in the amino acid class from that of the
reference strain. Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartic acid; Ile,
isoleucine; Gln, glutamine; Glu, glutamic acid; Gly, glycine; Leu, leucine; Lys, lysine;
Phe, phenylalanine; Pro, proline; Ser, serine; Thr, threonine; Val, valine.
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Sir—Corynebacterium ulcerans is increas-
ingly recognized as an emerging pathogen
in various countries, including the United
States [1], the United Kingdom [2], Japan
[3], The Netherlands [4], Switzerland [5],
and Italy [6]. In some of these countries,
C. ulcerans is now the leading cause of
classical pharyngeal diphtheria [2]. The
ability of C. ulcerans infection to mim-
ic diphtheria is explained by the fact
that C. ulcerans—similar to Corynebacte-
rium diphtheriae and Corynebacterium
pseudotuberculosis—carries lysogenic b-
corynephages coding for the diphtheria
toxin (DT). We previously described 2 C.
ulcerans isolates that were associated with
cases of extrapharyngeal diphtheria (one
was isolated from a cutaneous infection
and the other caused lethal necrotizing si-
nusitis); sequencing of the respective tox
gene of both strains revealed differences
in nucleotide and amino acid sequences
between C. diphtheriae and C. ulcerans
DTs [7].
Here, we report a case of classical
diphtheria caused by C. ulcerans in a 53-
year-old woman who developed severe
pharyngeal swelling and a whitish pseu-
domembrane. Her family practitioner
obtained a swab specimen from the le-
sion, which grew C. ulcerans (API code
0111326), as detected by biochemical
methods (API Coryne; bioMe´rieux) and
16S rRNA gene sequencing. The presence
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of DT was tested both by tox PCR and an
Elek test, as described elsewhere [7]. Be-
cause of the severity of the swelling, the
patient was referred to an ear, nose, and
throat specialist who treated the infection
with 2 injections of penicillin (1.2 million
units). The patient recovered completely.
She had received a complete course of pri-
mary immunizations during childhood;
however, booster immunizations were
never administered.
Because no sequence data are available
for the tox gene of C. ulcerans associated
with classical pharyngeal diphtheria, we
sequenced the complete tox gene of this
strain (X959; GenBank accession num-
ber AY703827) and compared the amino
acid sequence with those of a C. diphthe-
riae strain (GenBank accession number
V01536) and 2 C. ulcerans strains, A2911
and A6361, that cause extrapharynge-
al disease (GenBank accession numbers
AY141013 and AY141014, respectively)
[7]. The C. diphtheriae strain and the 3 C.
ulcerans strains differed from each other
in 26 amino acids (homology, 95.4%), 13
of which belonged to different amino acid
classes (table 1). Most differences were lo-
cated in the B fragment of the DT. In 3
positions (aa14, aa31, and aa262), the DT
from C. ulcerans X959 was unique, har-
boring an amino acid that was not present
in the other DTs. Interestingly, the DTs
from both the C. diphtheriae and the C.
ulcerans X959 strains have a serine in po-
sition 22 of the A fragment and an alanine
in position 183 of the A fragment, whereas
the DTs of the C. ulcerans A2911 and
A6361 strains have a leucine in position
22 of the A fragment and a glutamine po-
sition 183 of the A fragment. Because these
are the only differences between the DTs
of the C. diphtheriae and C. ulcerans X959
strains, on the one hand, and the DTs of
the 2 extrapharyngeal C. ulcerans strains,
on the other hand, it might be speculated
that these amino acids could be involved
in pseudomembrane formation; however,
loss of activity in mutated C. diphthe-
riae DT has not yet been linked to aa22
or aa183.
The difference between C. diphtheriae
and C. ulcerans tox genes was further cor-
roborated by C. ulcerans tox–specific PCR
using primers DT1 with 1467R or 1586R,
respectively [7], yielding a positive PCR
result only for the 3 C. ulcerans strains,
and not for the C. diphtheriae strain.
To our knowledge, this is the first report
of classical diphtheria caused by C. ulcer-
ans in Germany since the description of
this species in 1995 [8]. Moreover, the se-
quence data on the isolated strain that
caused classical diphtheria in the patient
we describe confirm the previous results
that we obtained for 2 isolates of C. ul-
cerans that caused extrapharyngeal in-
fections, suggesting that DTs from C.
diphtheriae and C. ulcerans are different,
independent from an association with
pharyngeal or extrapharyngeal disease. In
addition, this first sequenced DT from a
C. ulcerans isolate associated with classical
diphtheria indicates that C. ulcerans DT
amino acid sequences are less well con-
served than their C. diphtheriae counter-
parts [9].
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Influence of GB Virus Type C
and HIV Coinfection on gd
T cells
Sir—GB virus type C (GBV-C) coinfec-
tion has been associated with decreased
mortality and better outcome for human
immunodeficiency virus (HIV)–infected
persons [1, 2]. However, recent studies
suggest that GBV-C coinfection can be
secondary to HIV-disease progression,
rather than an independent prognostic
factor for such progression [3]. Sev-
eral immunological mechanisms have
been proposed that associate GBV-C coin-
fection with the interference of HIV rep-
lication, such as reduction of CCR5 che-
mokine receptor expression, induction of
antiviral chemokines, preservation of Th1
immune-response, and other mechanisms
of viral interference [4, 5]. In a recent ar-
ticle by Sathar et al. [6], it has been shown
that GBV-C coinfection in HIV-infected
persons was associated with increased fre-
quency of gd T cells. An accompanying
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Figure 1. Frequencies and absolute numbers of circulating gd T cells in 50 healthy control subjects (HIV) and 47 HIV-infected patients (HIV+),
of whom 34 tested negative for GB virus type C (GBV-C) RNA in plasma (GBV-C) and 13 tested positive (GBV-C+). A, Percentage of circulating gd
T cells. B, Absolute number of circulating gd T cells. C, Absolute number of circulating Vd1 T cells. D, Absolute number of circulating Vd2 T cells.
Bars, Medians and interquartile ranges. Comparison between GBV-C–infected and GBV-C–uninfected HIV patients groups was made by a nonparametric
Mann-Whitney test (Prism 4; GraphPad Software). NS, P not significant.
editorial commentary [7] suggested that
GBV-C coinfection may trigger a gd T cell
immune response that, in turn, may in-
duce a slower HIV replication rate and/or
a more effective anti-HIV Th1 immune
response.
Since we previously observed that a
subset of gd T cells expressing the Vd2 T
cell receptor may play a protective role
during HIV infection by producing non-
cytolytic antiviral factors [8], and that
this gd T cell subset is generally depleted
in HIV-infected patients [9], we have in-
vestigated whether GBV-C coinfection
was associated with altered frequencies of
gd T cell subsets in a cohort of HIV-
infected patients, which may account for
the beneficial influence of GBV-C coin-
fection on the course of HIV disease. The
frequency of circulating gd T cells and
their subset composition was analyzed by
flow cytometry in 47 HIV-infected pa-
tients (28 male and 19 female; median
age, 41 years; age range, 28–66 years) at-
tending the outpatient facility at the Na-
tional Institute for Infectious Diseases
“Lazzaro Spallanzani” in Rome. In our
cohort, 41 subjects (87.2% of 47) had
been receiving successful antiretroviral
treatment for at least 2 years prior to the
study. The presence of GBV-C RNA in
plasma was determined by nested RT-
PCR, according to a previously estab-
lished method [1]. gd T cell distribution
in such subjects was compared according
to their GBV-C infection status (figure
1). The 2 study groups were similar with
respect to their demographic character-
istics (data not shown). To establish ref-
erence values for gd T cell distribution
in peripheral blood, 50 blood samples
from healthy donors were obtained from
the Immunohaematology Laboratory at
the Forlanini-San Camillo Hospital in
Rome.
As shown in figure 1, the gd T cell sub-
set distribution was significantly altered by
HIV infection, as expected (figure 1, pan-
els C–D). In fact, the Vd1 T cell subset
was significantly augmented in the pe-
ripheral blood of HIV-infected subjects [9,
10]. Furthermore, the increase of Vd1 T
cells was concomitant with a decrease of
Vd2 T cells [9, 11, 12]. However, com-
parison of gd T cell subset distribution in
HIV-infected subjects, grouped according
to their GBV infection status indicated
that the increase in gd T cells occurred
independently of GBV-C coinfection (fig-
ure 1, panel C) and that GBV-C coinfec-
tion had no role in the specific deletion
of T cell receptors (figure 1, panel D).
In our cohort of HIV-infected subjects,
we observed that Vd2 T cell exhaustion
and Vd1 T cell increase are not correlated
with GBV-C coinfection. Thus, other
mechanisms are likely to be involved in
interactions between GBV-C and HIV
infections.
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Table 1. Comparison of mean lymphocyte subset indices in HIV-
infected patients with and without GB virus type C infection.
Lymphocyte subset







Percentage 26.70  8.30 26.64  8.67 NS
Count, cells/mL 461.12  163.28 478.42  181.22 NS
CD8
Percentage 48.47  10.08 48.70  10.78 NS
Count, cells/mL 680.83  320.36 862.52  354.48 NS
CD4:CD8 ratio 0.58  0.25 0.59  0.28 NS
CD3
Percentage 80.0  4.17 70.99  19.76 .015
Count, cells/mL 1395.45  366.79 1451.29  571.37 NS
CD30
Percentage 35.45  17.86 50.59  9.20 .041
Count, cells/mL 577.75  307.64 823.88  392.00 NS
gd T
Percentage 3.22  1.30 2.15  1.08 .052
Count, cells/mL 53.11  18.35 39.15  29.12 NS
NOTE. NS, not significant.
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Reply to Martini et al.
Sir—We read with interest the findings of
Martini et al. [1] regarding the influence
of GB virus type C (GBV-C) coinfection
of gd T cells in human immunodeficiency
virus (HIV)–infected patients. The use of
direct human-to-human microbial trans-
mission as therapy for infectious diseases
may seem anachronistic, but several stud-
ies have suggested that infection with 1
microbe can alter the disease expression
of another pathogen, including HIV [2].
To date, 11 clinical studies have associated
GBV-C coinfection with slower progres-
sion to acquired immunodeficiency syn-
drome, longer life, and improved response
to antiretroviral therapy in HIV-infected
individuals [3–6]. Several mechanisms
have been proposed: namely, the induc-
tion of anti-HIV cytokines and chemo-
kines [3, 4, 7], the stimulation of anti-HIV
cytotoxic T lymphocyte response [8], and
the preservation of Th1 lymphocyte re-
sponse [9]. In our limited observational
study [10], we reported no significant dif-
ferences in lymphocyte subsets between
HIV-infected African mothers coinfected
with GBV-C and those not coinfected (ta-
ble 1). We observed no significant differ-
ence in absolute gd T cell counts between
HIV-infected mothers coinfected with
GBV-C and those not coinfected. How-
ever, we reported a marginally significant
difference ( ) between the relativeP ! .052
gd T cell counts of the 2 groups (table 1).
On the basis of this observation and the
cognizance of the potential role of gd T
cells in HIV infection [11], we hypothe-
sized that another anti-HIV mechanism
may be associated with GBV-C infection.
Martini et al. [1], on the other hand, re-
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port a marginally significant difference
( ) in absolute gd T cell counts [1,P ! .05
figure 1B] and no significant difference in
relative counts [1, table 1A] between the
2 groups. Although Martin et al. [1] re-
ports a significant difference in gd T cell
subsets between the study groups, we did
not measure gd T cell subsets. In addition,
there are other differences between our
respective studies. In their study [1], 41
(87.2%) of 47 HIV-infected subjects had
been receiving successful antiretroviral
treatment for a period of 2 years. In our
study [10], all HIV-infected African moth-
ers were antiretroviral-naive; the only cri-
terion that determined whether patients
could participate was HIV infection status;
the study populations are composed of
different racial groups; and the majority
of HIV and GBV-C infections in KwaZulu
Natal are clade C and genotype 5, respec-
tively. Our data concurs with the obser-
vations reported by Martini et al. [1], and
we agree that some other factor or factors
besides GBV-C infection may play a role
in altering the gd T lymphocyte subsets in
HIV-infected individuals.
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Coinfection with HIV and
Human T Lymphotropic Virus
Type 1: What Is the Real
Impact on HIV Disease?
Sir—We read with interest the article by
Beilke et al. [1] summarizing their find-
ings of an observational study of a group
of HIV-infected patients, some of whom
were coinfected with human T lympho-
tropic virus types 1 (HTLV-1) and/or 2
(HTLV-2). The authors focus the clin-
ical outcomes and survival probabilities
among coinfected patients, and the final
conclusions reinforce previous evidence of
the absence of a significant impact of
HTLV-2 coinfection on AIDS progression
[2, 3]. They conclude that HTLV-2 co-
infection is associated with some degree
of protection against disease progression
for such patients, with a consequent
greater duration of survival. Other find-
ings include the increased incidence of
some clinical events among coinfected pa-
tients, such as myelopathy, urinary tract
infection, peripheral neuropathy, throm-
bocytopenia, and bronchitis, compared
with persons who were infected with HIV
alone. In addition, Beilke et al. [1] confirm
already-reported data on higher CD4+ cell
counts among coinfected patients [4].
However, the absence of an impact of
HTLV-1 coinfection on survival was an
unexpected finding. Our previous expe-
rience in evaluating a similar population
with a similar duration of follow-up
yielded the opposite result. We evaluated
the duration of survival for 132 HIV-
infected patients (63 of whom where co-
infected with HTLV-1) who were observed
at our clinics, with a significant difference
in the time to death that favored HIV-
monoinfected subjects, which remained
after adjustment for injection drug use [5].
One possible explanation for such dis-
crepancies could reside in the population
studied: our study included mainly pa-
tients in the pre-HAART era. The use of
antiretroviral drugs probably modifies the
natural history of coinfection, because the
proper therapy for HIV infection could
mask the potentially additive effects of
HTLV-1 coinfection on disease progres-
sion. Beilke et al. [1] stated that they ad-
justed the analysis for the use of antiret-
roviral drugs, but there is no description
in the article on the duration of therapy
or follow-up or on the time that therapy
was started for monoinfected and co-
infected patients. In addition, the strati-
fication of CD4+ cell counts into 3 groups
(!200, 200–500, and 1500 cells/mL) can
mask some important difference between
HIV-monoinfected and HIV-HTLV–co-
infected patients. The range of CD4+ cell
counts in the 3 groups is large enough to
include some quite different patients.
Another important question regards the
matching of patients by CD4+ cell count:
if Beilke et al. [1] conclude that this pa-
rameter is modified by coinfection, then
we do not think it is the best approach to
compare groups. Because CD4+ cell counts
are expected to be higher in HIV-HTLV–
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coinfected patients, and because coinfec-
tion can be associated with immune dys-
function, matching patients by immune
markers is not a good strategy. The au-
thors recognize that they were not able to
define the best threshold point to rec-
ommend the commencement of HIV
therapy for such patients for these reasons.
The study is very important because it
raises this and other questions. The sta-
tistical analysis is quite strong and well
designed, but some of the study’s points
remained unclear. Although the authors
recognize some limitations of the study,
they affirm the absence of a clinical impact
of coinfection on AIDS progression. We
believe that the available data are still too
weak to confirm that theory. As correctly
stated at the end of the article, these ques-
tions probably will be answered only
through prospective studies.
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Reply to Brites et al.
Sir—We appreciate the correspondence
by Brites et al. [1] and would like to pro-
vide additional clarification concerning
several points they raised. Our study [2],
which focuses on clinical outcomes and
survival probabilities among patients
coinfected with HIV and human T lym-
photropic virus types 1 and 2 (HTLV-1
and HTLV-2, respectively), actually ar-
rives at conclusions that are somewhat
different than those of the previous stud-
ies cited by Brites et al. [1]. In contrast
to the reports of Hershow et al. [3] and
Giacomo et al. [4], who found no dif-
ferences in survival outcomes, our find-
ings indicate improved duration of sur-
vival and delayed progression to AIDS
among patients coinfected with HIV and
HTLV-2. A similar trend was observed
among patients coinfected with HIV and
HTLV-1, but the results did not reach
statistical significance. Several reasons
may exist for observed differences among
various cohort studies. First, treatment
effects at different study sites could have
an impact on survival trends and rates of
disease progression. In the New Orleans
cohort analysis, we were careful to gen-
erate a matched cohort study, in which
exposure to antiretroviral therapy and
CD4+ cell count was controlled for at
baseline, as well as over time. The mean
durations (SD) of exposure to antiret-
roviral therapy among HIV–HTLV-1–
coinfected patients, HIV–HTLV-2–coin-
fected patients, and HIV-monoinfected
patients were ,20.02 30.10 24.21
, and months, re-37.03 22.79 34.23
spectively. The year of initiation of anti-
retroviral therapy did not differ signifi-
cantly among the 3 groups.
Second, the prior studies did not report
whether there was control for baseline
CD4+ cell count or viral load. We found
no differences in baseline plasma HIV
RNA levels (although viral load data were
only available for patients who entered
the cohort after 1996), and our case-con-
trol cohort was matched for baseline
CD4+ cell count. We elected to stratify by
CD4+ cell count category (i.e., !200,
200–500, and 1500 cells/mL). Brites et al.
[1] expressed concern that these ranges
might be too wide. Therefore, we ex-
amined the mean and median CD4+ cell
count range among the 3 strata, and we
found almost identical results among the
groups. In the CD4+ cell count stratum
of 200–500 cells/mL, for example, the
mean (SD) CD4+ cell counts were
cells/mL (median, 362.0345.3 77.1
cells/mL; range, 212–497 cells/mL) for
HIV–HTLV-1–coinfected patients, 344.7
 84.8 cells/mL (median, 340.0 cells/mL;
range, 200–500 cells/mL) for HIV–HTLV-
2–coinfected patients, and 350.0 83.7
cells/mL (median, 340.1 cells/mL; range,
202–494 cells/mL) for HIV-monoinfected
patients. Although coinfected and mon-
oinfected patients were matched with re-
spect to CD4+ cell count at baseline, the
CD4+ cell count could have changed over
time (which we also demonstrated), and,
therefore, the CD4+ cell count over time
was also controlled for in the survival
analyses. We contend that matching for
baseline CD4+ cell count is a rational
method to compare survival and disease
progression, because there may be qual-
itative and quantitative differences in
CD4+ cell count that account for diver-
gences in outcomes.
In our analysis of mortality and dura-
tion of AIDS-free survival, we attempted
to account for potential survivor-treat-
ment selection bias by matching for
CD4+ cell count at baseline/time of clinic
entry. This is one approach that is com-
monly used in observational studies [5]
to eliminate potential survival bias, be-
cause the final model compares persons
in the different treatment or exposure
groups who started in similar physical
conditions and (theoretically) survive to
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the same time point or have similar op-
tions for treatment and prolonged sur-
vival or AIDS-free time [5–7]. Survivor-
treatment bias should be accounted for
when interpreting the results of HIV co-
hort studies.
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Fatal Salmonella Pulmonary
Arteritis in a Patient
with Eisenmenger Syndrome
Sir—Arterial infection is the most serious
complication of salmonellosis [1]. Sal-
monella arterial infections can involve the
thoracic and abdominal aortas and the pe-
ripheral arteries. Infection of the pulmo-
nary trunk or its major branches is rare
[2, 3]. The mortality rate for patients with
mycotic pulmonary aneurysm (pulmo-
nary arteritis) is reported to be 150%, and
most of the causative pathogens are gram-
positive bacteria, including Staphylococcus
aureus and streptococci [3]. To our knowl-
edge, Salmonella species have never been
reported as a cause of pulmonary arteritis
in the English-language literature.
The patient was a 61-year-old woman
who had received a diagnosis of atrial sep-
tal defect with Eisenmenger syndrome.
She was admitted to a regional hospital
(hospital A) because of fever, severe cough,
and dyspnea. The patient was treated for
asthma with secondary infection. Intra-
venous cefazolin (1 g q8h) was adminis-
tered. On the eighth day of hospitalization
at hospital A, the patient developed he-
moptysis and severe chest pain and was
transferred to our hospital.
Physical examination revealed a body
temperature of 37C, blood pressure of
120/70 mm Hg, a regular pulse rate of 90
beats/min, and a respiratory rate of 18
breaths/min. There was a grade III/VI sys-
tolic murmur heard along the left sternal
border and apex. Chest palpation revealed
a right parasternal heave. Except for club-
bing fingers and cyanosis, the remainder
of the findings of the examination were
unremarkable. Laboratory data revealed a
WBC count of cells/mL (with317.45 10
92.8% neutrophils), a hemoglobin level of
16.4 g/dL, and a platelet count of 154
103 platelets/mL. Blood chemistry exam-
ination revealed a urea nitrogen value
of 9.3 mg/dL, a creatinine level of 0.7
mg/dL, an albumin level of 3.2 g/dL, and
a C-reactive protein level of 10.37 mg/dL.
Chest radiographs revealed cardiomegaly
and a bulging pulmonary conus. The bi-
lateral pulmonary arteries were also di-
lated (figure 1). A hazy, ill-defined shadow
extending upward from the pulmonary
conus was noted. Chest CT with contrast
enhancement revealed markedly dilated
pulmonary trunk and bilateral central
pulmonary arteries (figure 1). An abnor-
mal consolidation around the left pul-
monary artery near the hilar area was
demonstrated. The consolidation con-
sisted of inhomogeneous masses with ir-
regular peripheral enhancement, which
was consistent with mural thrombus and
peri-arterial inflammation. There was an
irregular tract extending from the pul-
monary artery into the consolidation
mass, suggesting extravasation of the in-
fected pulmonary artery. Echocardiog-
raphy demonstrated a secundum atrial
septal defect of 22 mm in diameter and
no evidence of infective endocarditis.
The patient developed fever, repeated
hemoptysis, and hypotension during the
initial 3 days of hospitalization. The in-
fected pulmonary arteritis (pulmonary
mycotic pseudoaneurysm) was considered
to have an impending rupture with a hem-
orrhage that was probably life-threatening.
Surgical resection was necessary but risky
because of pulmonary hypertension with
Eisenmenger syndrome. The patient was
considered to be a candidate for combined
heart-lung transplantation.
Intravenous ceftriaxone (1 g q12h) was
administered on the first day of hospital-
ization, because 2 sets of blood cultures
from hospital A were positive for Sal-
monella serogroup D (nontyphoid). The
isolate was susceptible to ampicillin, cef-
triaxone, and ofloxacin but resistant to
trimethoprim-sulfamethoxazole, as deter-
mined by the disk diffusion method. The
patient was afebrile and in stable clinical
condition (subsidence of chest pain and ab-
sence of hemoptysis) on the fourth day of
hospitalization. Unfortunately, the patient
developed a sudden onset of intractable
pulmonary hemorrhage and died on the
seventh day of hospitalization, despite im-
mediate and vigorous resuscitative efforts.
Pulmonary hypertension with Eisen-
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Figure 1. Left, Chest radiograph showing cardiomegaly and a bulging pulmonary conus, with a hazy, ill-defined shadow extending upward from
the pulmonary conus (arrow). Right, Chest CT with contrast enhancement revealing an abnormal consolidation around the dilated left pulmonary artery
near the hilar area. There was an irregular tract extending from the pulmonary artery into the consolidation mass, suggesting extravasation (arrow
head) of the infected pulmonary artery.
menger syndrome leads to exposure of the
pulmonary vasculature to systemic arterial
pressure and results in aneurismal dila-
tion. The responsible microorganism has
an inclination toward diseased vascular
walls, and mural thrombi would provide
an ideal environment for the seeding and
growth of the microorganisms. The clin-
ical course and management of infect-
ed pulmonary arteritis is not well docu-
mented because of the rarity of cases.
From experience with the management of
aortic aneurysms infected with Salmonella
species [4–6], survival rates appear to im-
prove among patients who receive com-
bined medical treatment and surgical in-
tervention. In the collective case study by
Hsu et al. [4], none of the 20 patients who
had combined medical and surgical treat-
ment died. However, 2 of the 4 patients
treated with antibiotics alone died.
Complex congenital heart disease with
indolent Salmonella infection exposed our
patient to a life-threatening situation.
Early surgical interventions, including re-
section of the infected left pulmonary ar-
tery and wide debridement of adjuvant
tissue, followed by combined heart-lung
or lung transplantation [7], were crucial
in our case because of the impending
rupture with probable life-threatening
hemorrhage. Unfortunately, the patient
had intractable pulmonary hemorrhage
and died, despite administration of ap-
propriate antibiotic treatment 1 week be-
fore death.
In conclusion, Salmonella species
should be included in the list of pathogens
that can cause pulmonary arteritis. Ag-
gressive antibiotic treatment and intensive
surgical intervention are essential to avoid
death due to rupture of the aneurysm.
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Background for Different
Use of Antibiotics in
Different Countries
Sir—We read the article about the quan-
titative and qualitative differences in an-
tibiotic prescribing between British Co-
lumbia and Denmark [1] with great
interest. We agree with the authors that
the increasing use of fluoroquinolones and
new macrolides is worrying, because it
may increase the risk for emergence of a
greater number of resistant microorgan-
isms. With use of a different method, we
performed a study that compared the pre-
scribing of antibiotics in Spain and Den-
mark [2]. In Spain, a similar phenomenon
to the one in British Colombia was ob-
served, with an increase in the use of new
antibiotics.
We agree that among the main reasons
for the difference in antibiotic use are the
different opinions and traditions regard-
ing how to treat infections that exist in
different countries. We have verified this
by comparing, for example, the existing
general practice guidelines for the treat-
ment of streptococcal tonsillitis or of the
exacerbation of chronic obstructive pul-
monary disease in Denmark and Spain.
In Denmark, narrow-spectrum penicillin
is recommended for both infections,
whereas in Spain, only broad-spectrum
antibiotics are recommended. A vicious
circle is thus created. In an attempt to
cover these pathogens, the prescribing of
broad-spectrum antibiotics favors a more
rapid expansion of resistant microorgan-
isms. In Denmark, where rates of resis-
tance are very low, narrow-spectrum an-
tibiotics are still the most frequently used
antibiotics in primary health care, thus
perpetuating a low prevalence of resistant
microorganisms.
We would like to emphasize the fact that
different methods of organizing health
care services may have a considerable in-
fluence on the pattern of antibiotic pre-
scribing. Variables such as the type of
health care financing system, the number
of doctors per inhabitant, and the average
time spent with the patient may lead to
different prescribing habits. It is known,
for example, that countries with a greater
number of doctors per inhabitant use
more antibiotics than do countries with a
smaller number of doctors per inhabitant
[3], and that doctors who spend more
time with their patients prescribe fewer
antibiotics [4]. The permissive policy of
the sale of antibiotics without a prescrip-
tion (i.e., over-the-counter policy), which
exists in Spain but not in Denmark, is
another potential reason for the difference.
Other factors to take into account are the
number of pharmacies per inhabitant (10
times greater in Spain than in Denmark),
the pressures from the pharmaceutical in-
dustry, and the antibiotics available. In
Spain, penicillin V is only marketed in
doses of 200 mg and 600 mg, a fact about
which the pharmaceutical industry’s rep-
resentatives do not inform doctors. Dif-
ferent policies concerning subsidization of
antibiotics may also have an influence. In
Denmark, fluoroquinolones and cephal-
osporines are not subsidized by the na-
tional health care service.
In conclusion, we believe that different
methods of organizing health care ser-
vices, different subsidization policies, and
different impacts of pharmaceutical mar-
keting should be taken into account when
trying to explain differences in the pattern
of antibiotic prescribing. These factors
may indeed explain some of the differ-
ences that exist between neighboring
countries, such as between Belgium and
The Netherlands [5]. Antibiotic resistance
may spread across borders. Countries with
a high prevalence of resistance may serve
as a source of bacterial resistance for coun-
tries with low prevalence. Studies com-
paring consumption of antibiotics in dif-
ferent countries are therefore important,
and the article by Patrick et al. [1] con-
tributes to our understanding in this field.
However, more knowledge about the
background of these differences is needed
to stem the increasing use of new anti-
biotics and the increasing prevalence of
resistant microorganisms.
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Immunosorbent Assays for a
Patient with Gastrointestinal
Graft-versus-Host Disease
Taking a Nutrient Containing
Soybean Protein
Sir—A direct double antibody sandwich
ELISA (Platelia Aspergillus; BioRad) for
galactomannan antigen has a sensitivity of
67%–100% and a specificity of 81%–99%
for the diagnosis of invasive aspergillosis
(IA) [1]. The mechanism of reported false-
positive results remains to be clarified [2,
3]. We describe a patient who had con-
secutive positive galactomannan ELISA re-
sults without any signs of IA.
A 31-year-old woman with acute lym-
phoblastic leukemia underwent hemato-
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Figure 1. Optical density index (ODI) for galactomannan ELISA. The dotted line indicates an
ODI of 1.5, which is the cutoff for the normal value. The thick black bar denotes the period during
which Racol (Otsuka Pharmaceutical) was administered.
poietic stem cell transplantation from an
HLA-identical sibling in December 2003.
She received busulfan and cyclophos-
phamide for conditioning, as well as cy-
closporin and short-term methotrexate
for graft-versus-host disease (GVHD) pro-
phylaxis. Engraftment occurred on day 14
of transplantation. Diffuse erythema and
diarrhea developed, and grade 3 acute
GVHD was diagnosed after skin biopsy.
We initiated methylprednisolone therapy
(1 mg/kg) on day 20, to which GVHD
gradually responded.
The patient had persistent appetite loss
and taste disturbance. On day 44, we
started giving the patient the liquid nu-
trient Racol (Otsuka Pharmaceutical; 200
mL q.d.), which contains the lowest
amount of fiber among our formulary nu-
trients. Because acute GVHD that requires
corticosteroid treatment is associated with
a significant risk of IA, we monitored the
galactomannan ELISA results, which were
negative on day 24. On day 47, the optical
density index (ODI) was 14.0 (normal
value, !1.5) (figure 1). The patient had no
fever or respiratory symptoms. Chest CT
and blood culture results were negative.
We suspected that Racol was the cul-
prit in the false-positive galactomannan
ELISA results. After Racol was withheld
for 3 days, the ODI decreased to 1.7. To
identify the association, we administered
Racol to the patient on day 66 and to a
healthy control subject. The patient ex-
perienced a subsequent increase in the
ODI, whereas the findings of serial mon-
itoring examinations remained normal for
the control subject. After the use of Racol
was discontinued, the ODI normalized
again in the patient. She never received
herbal medicines or piperacillin-tazobac-
tam, which is associated with a high rate
of false-positive galactomannan antigen
test results [4]. Racol and its constituents
(i.e., soybean protein, lactic acid casein,
maltodextrin, and water) were submitted
to galactomannan ELISA testing. Racol,
soybean protein, and lactic acid casein
yielded positive results, with ODIs of 15.0,
15.0, and 4.8, respectively. Cultures of the
products did not yield Aspergillus species.
Galactomannan contained in soybean
may have entered the patient’s circula-
tion, thus leading to the positive galac-
tomannan ELISA result; however, galac-
tomannan has high molecular weight
(range, 0.3–4 million Da) and is not ab-
sorbed through an intact intestinal mu-
cosa, as shown in our control subject.
Galactomannan become digestible after
hydrolysis by a-1,6-galactosidase and b-
1,4-mannanase, which humans do not
produce. The 2 possible ways to gain these
enzymes are external supplementation
and production by intestinal bacteria. Al-
though experiments involving pigs have
shown that the administration of the en-
zymes improved the digestibility of soy-
bean meal [5], Racol is not supplemented
with the enzymes. The other possibility is
that the antibiotic treatments increased
galactosidase- and mannanase-producing
intestinal bacteria, such as Bacteroides, Bi-
fidobacterium, and Lactobacillus species, to
enable digestion of galactomannan.
The disrupted intestinal mucosal bar-
rier secondary to GVHD in our patient
may have contributed to the translocation
of a larger amount of galactomannan-
degraded products than in the control
subject. Clinicians should be alert to the
possible false-positive results of galacto-
mannan ELISAs for patients with gastro-
intestinal GVHD who are taking nutrients
containing soybean protein.
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